New Business Opportunities in Bio/Pharma,
Medical Devices & Diagnostics

February 2015

Welcome to the February 2015 issue of PharmSource PERISCOPE

This monthly e-newsletter provides valuable insight to sales and marketing professionals who sell goods and services to bio/pharma, medical device or diagnostic companies. It helps you recognize new business opportunities and overcome sales obstacles.

Enjoy the February issue!

The PharmSource Team


PharmSource Lead Sheet Global Activity Report:

Lead Type January 2015 2015 YTD
Early Development 176 176
Late Development 112 112
Biologic 120 120
Small Molecule 286 286
Parenteral 144 144
Oral 108 108
New Financings 126 126
Total Drug Leads 490 490
Total Device &
Diagnostic Leads
131 131

*Total leads include acquisitions/alliances, company acquisition/alliances and events.


Pipeline Tip

Oramed Pharmaceuticals initiates IND-enabling studies and plans to file an IND and initiate a large Phase II trial in the US with ORMD-0901,an encapsulated oral formulation of exenatide for diabetes management, including reduction in blood glucose levels and inhibition of glucagon secretion. Learn more.

Lead Sheet Trivia Game: Play to Win!

by Brooke Wilson, Senior Research Analyst

Here at PharmSource, we want to make sure some fun goes along with the serious work. That’s why we created PharmSource Lead Sheet Deep Dive Trivia. It’s a fun way to test your skills using the database search engine – and in return you could win a $20 Starbucks gift card!

Our monthly trivia questions are emailed to you during the first week of each month from Blythe Moore, our awesome Director of Account Management. Each question highlights a way to identify relevant leads that meet particular criteria. We craft questions that call on you to use the database to identify new business opportunities based on various criteria like dosage forms, geographic regions, APIs, therapeutic areas, etc.

In doing this, you might see… read on

Follow the Money: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc. is a US public company that develops novel targeted therapeutics for cancer, age-related macular degeneration, and fibrotic diseases. This month they raised $36 million in the closing of an initial public offering.

What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to fund preclinical and clinical development and initiate manufacturing activities required for regulatory approval of product candidates, and that they rely on third parties for… Find out what sourcing opportunities may be ahead.

Increase Revenue by Aligning Sales and Marketing

Most large companies are very sales-oriented, yet may not also embrace marketing as an integral element to driving revenue. There’s significant data from many studies that shows the value of dual sales and marketing strategies in establishing stable long-term growth (rather than unstable short-term results).

Sales people tend to focus on quotas, immediate selling opportunities, and individual clients. The polestars for marketing people are different: they’re looking at strategic product and client mixes, assessing the longer-term… read on


Catching a Wave: How Much Will CMOs Benefit From Biosimilars?

The second wave of biosimilars is starting to hit the US and European markets. Biopharma companies are already starting to develop the third wave.

  • Only 10% of the first wave of biosimilars was outsourced. How much will CMOs benefit from the coming generations?
  • Can start-up biosimilar companies compete with Big Pharma and Big Generics?